Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Snyder

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|July 11, 2016
Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic LeukemiaMonzr M Al Malki, Ibrahim Aldoss, Tracey Stiller, et al.
ACS Medicinal Chemistry Letters|July 2, 2013
ABSOLUTE CONFIGURATION AND BIOLOGICAL PROPERTIES OF ENANTIOMERS OF CFTR INHIBITOR BPO-27David S Snyder, Lukmanee Tradtrantip, Sailaja Battula, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 30, 2009
Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosisDavid S Snyder, Joycelynne Palmer, Karl Gaal, et al.
American Journal of Clinical Pathology|September 19, 2007
Clinical and pathologic analysis of 16 cases of relapsed chronic myeloid leukemia after stem cell transplantationQin Huang, Yaping Wu, David S Snyder, et al.
Blood|February 11, 2003
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatmentRavi Bhatia, Melissa Holtz, Ning Niu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2006
Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosisDavid S Snyder, Joycelynne Palmer, Anthony S Stein, et al.
Blood|November 23, 2006
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemiaPaul A Carpenter, David S Snyder, Mary E D Flowers, et al.
Haematologica|August 1, 2020
Dynamics of mutations in patients with essential thrombocythemia treated with imetelstatElisabeth Oppliger Leibundgut, Monika Haubitz, Bart Burington, et al.
Cancer Cell|May 19, 2010
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylateBin Zhang, Adam C Strauss, Su Chu, et al.
The New England Journal of Medicine|September 3, 2015
Telomerase Inhibitor Imetelstat in Patients with Essential ThrombocythemiaGabriela M Baerlocher, Elisabeth Oppliger Leibundgut, Oliver G Ottmann, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Clinical Lymphoma, Myeloma & Leukemia|July 11, 2016
Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic LeukemiaMonzr M Al Malki, Ibrahim Aldoss, Tracey Stiller, et al.
ACS Medicinal Chemistry Letters|July 2, 2013
ABSOLUTE CONFIGURATION AND BIOLOGICAL PROPERTIES OF ENANTIOMERS OF CFTR INHIBITOR BPO-27David S Snyder, Lukmanee Tradtrantip, Sailaja Battula, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 30, 2009
Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosisDavid S Snyder, Joycelynne Palmer, Karl Gaal, et al.
American Journal of Clinical Pathology|September 19, 2007
Clinical and pathologic analysis of 16 cases of relapsed chronic myeloid leukemia after stem cell transplantationQin Huang, Yaping Wu, David S Snyder, et al.
Blood|February 11, 2003
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatmentRavi Bhatia, Melissa Holtz, Ning Niu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2006
Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosisDavid S Snyder, Joycelynne Palmer, Anthony S Stein, et al.
Blood|November 23, 2006
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemiaPaul A Carpenter, David S Snyder, Mary E D Flowers, et al.
Haematologica|August 1, 2020
Dynamics of mutations in patients with essential thrombocythemia treated with imetelstatElisabeth Oppliger Leibundgut, Monika Haubitz, Bart Burington, et al.
Cancer Cell|May 19, 2010
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylateBin Zhang, Adam C Strauss, Su Chu, et al.
The New England Journal of Medicine|September 3, 2015
Telomerase Inhibitor Imetelstat in Patients with Essential ThrombocythemiaGabriela M Baerlocher, Elisabeth Oppliger Leibundgut, Oliver G Ottmann, et al.
Pageof 5